Cellectis spikes on takeout rumor

Cellectis S.A. (Euronext:ALCLS; NASDAQ:CLLS) gained $6.67 (16%) to $47.66 on NASDAQ Thursday on media reports that the company is discussing a potential sale to Pfizer Inc. (NYSE:PFE). Cellectis and Pfizer declined to comment.

Cellectis received $80 million up front in a June 2014 deal giving Pfizer a license to develop cancer immunotherapies using the biotech's CAR T cell technology (see BioCentury, July 14, 2014). ...